In this segment, Dr. Alexander Spira and Dr. Ticiana Leal explore how emerging neoadjuvant strategies are influencing the management of early-stage EGFR-mutated nonโsmall cell lung cancer (NSCLC). The discussion focuses on the growing relevance of trials such as NeoADAURA and how they are reshaping treatment planning in resectable disease. Dr. Leal highlights the increasing importance of obtaining comprehensive biomarker testing at the time of initial diagnostic biopsy, rather than waiting for surgical specimens, to ensure that targeted treatment options can be considered earlier in the disease course. The panel discusses how earlier identification of EGFR mutations enables more informed multidisciplinary decision-making, particularly when evaluating the role of neoadjuvant therapy. This evolving approach reflects a shift toward integrating molecular insights upfront to optimize sequencing strategies and improve outcomes in patients with EGFR-mutated NSCLC in the curative-intent setting.
